PerkinElmer to acquire antibodies and reagents manufacturer BioLegend

PerkinElmer has signed a cash and stock deal worth around $5.25 billion to acquire BioLegend, a California-based antibodies and reagents manufacturer. BioLegend caters to academic ... Read More